Aadi Bioscience, Inc. (AADI)

NASDAQ: AADI · IEX Real-Time Price · USD
14.50
+0.51 (3.65%)
At close: Oct 4, 2022 4:00 PM
14.49
-0.01 (-0.07%)
After-hours: Oct 4, 2022 5:18 PM EDT
3.65%
Market Cap 304.74M
Revenue (ttm) 6.74M
Net Income (ttm) -135.36M
Shares Out 21.02M
EPS (ttm) -8.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 78,309
Open 14.27
Previous Close 13.99
Day's Range 14.10 - 14.60
52-Week Range 11.00 - 32.50
Beta n/a
Analysts Buy
Price Target 44.37 (+206.0%)
Earnings Date Nov 8, 2022

About AADI

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. [Read more...]

Industry Biotechnology
Founded 2011
Employees 67
Stock Exchange NASDAQ
Ticker Symbol AADI
Full Company Profile

Financial Performance

In 2021, AADI's revenue was $1.12 million, a decrease of -92.32% compared to the previous year's $14.58 million. Losses were -$110.09 million, 3,065.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for AADI stock is "Buy." The 12-month stock price forecast is 44.37, which is an increase of 206.00% from the latest price.

Price Target
$44.37
(206.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing

LOS ANGELES , Sept. 22, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with altera...

1 week ago - PRNewsWire

Aadi Bioscience Announces Participation in Upcoming September Investor Conferences

LOS ANGELES , Sept. 1, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetical...

1 month ago - PRNewsWire

Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update

FYARRO® (nab-sirolimus) net product sales reached $3.4 million for the second quarter of 2022 PRECISION 1 Phase 2 tumor-agnostic registration-directed trial continues enrollment and rapid site activatio...

1 month ago - PRNewsWire

Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update

Company to Host Conference Call and Webcast on August 10 LOS ANGELES , July 28, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercia...

2 months ago - PRNewsWire

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined can...

3 months ago - GlobeNewsWire

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference

LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined can...

4 months ago - GlobeNewsWire

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined canc...

4 months ago - GlobeNewsWire

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to...

Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure Target tumor reductions observed in adv...

4 months ago - GlobeNewsWire

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference

LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined canc...

4 months ago - GlobeNewsWire

UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update

LOS ANGELES, May 12, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined canc...

4 months ago - GlobeNewsWire

Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update

LOS ANGELES, May 12, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined canc...

4 months ago - GlobeNewsWire

Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

LOS ANGELES, May 09, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined canc...

4 months ago - GlobeNewsWire

Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services

J-Code, Effective July 1st, Will Enable a Streamlined Reimbursement Process for FYARRO™ J-Code, Effective July 1st, Will Enable a Streamlined Reimbursement Process for FYARRO™

5 months ago - GlobeNewsWire

Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022

Company to hold conference call on May 12th at 8:30 am EDT Company to hold conference call on May 12th at 8:30 am EDT

5 months ago - GlobeNewsWire

Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit

LOS ANGELES, April 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-d...

5 months ago - GlobeNewsWire

Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annu...

- First rigorous analysis estimates TSC1 and TSC2 definite impact alteration incidence in U.S. as approximately 12,000 advanced cancer patients in 2030

5 months ago - GlobeNewsWire

Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Pat...

FDA grants Fast Track designation for nab-sirolimus for the treatment of adult and adolescent patients with Tuberous Sclerosis Complex 1 and 2 (“TSC1” and “TSC2”) alterations FDA grants Fast Track desig...

6 months ago - GlobeNewsWire

Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

-FYARRO™ approved November 22, 2021 and launched February 23, 2022-

6 months ago - GlobeNewsWire

Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen's 42nd Annual Health Care C...

LOS ANGELES, March 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq:AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations...

7 months ago - GlobeNewsWire

Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with...

– FYARRO™ added to NCCN® Guidelines as the only preferred mTOR inhibitor to treat malignant PEComa – – PRECISION-1 tumor agnostic study for TSC1 or TSC2 alterations is open for enrollment –

7 months ago - GlobeNewsWire

Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference

LOS ANGELES, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathwa...

9 months ago - GlobeNewsWire

Aadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form Cancer

The FDA has approved Aadi Bioscience Inc's (NASDAQ: AADI) Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for perivascular epithelioid cell tumor (PEComa). The appro...

10 months ago - Benzinga

Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable o...

LOS ANGELES, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations...

10 months ago - GlobeNewsWire

UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tis...

LOS ANGELES, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers w...

10 months ago - GlobeNewsWire

Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncol...

LOS ANGELES, Nov. 13, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers w...

10 months ago - GlobeNewsWire